7 completed, 4 terminated, 1 active not recruiting. 12 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 7, Terminated 4, Active not recruiting 1 |
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Terminated 1 |
Follow utomilumab: new trials by email Literature Review of utomilumab trials Research Report on utomilumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma Cyclophosphamide, Fludarabine, Axicabtagene Ciloleucel - Relapsed/Refractory Large B-cell Lymphoma | Phase 1 | Terminated | Kite, A Gilead Company | 15 | 2018-11-20 | 2024-06-28 |
| Rituximab + Immunotherapy in Follicular Lymphoma Rituximab, Utomilumab, Avelumab - Follicular Lymphoma | Phase 1 | Terminated | Dana-Farber Cancer Institute | 24 | 2018-10-30 | 2025-02-06 |
| T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer Aldesleukin, CD8-Positive T-Lymphocyte, Cyclophosphamide - COL6A3 Positive, HLA-A*0201 Positive Cells Present | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 5 | 2018-09-04 | 2024-11-07 |
| Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Avelumab, Carboplatin - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma | Phase 1 | Completed | City of Hope Medical Center | 16 | 2018-06-08 | 2026-10-02 |
| Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer Cetuximab, Irinotecan Hydrochloride, Pharmacodynamic Study - Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8 | Phase 1 | Completed | M.D. Anderson Cancer Center | 34 | 2017-12-27 | 2026-01-06 |
| 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer Utomilumab, Trastuzumab, Ado-Trastuzumab Emtansine - HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma | Phase 1 | Completed | George W. Sledge Jr. | 18 | 2017-10-30 | 2022-10-19 |
| Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies Avelumab, Ivuxolimab, Radiation Therapy - Advanced Malignant Solid Neoplasm, Castration-Resistant Prostate Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 173 | 2017-08-02 | 2026-10-23 |
| A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) Avelumab, Utomilumab, PF-04518600 - Advanced Cancer | Phase 1 / Phase 2 | Terminated | Pfizer | 409 | 2015-11-09 | 2024-07-30 |
| A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors PF-05082566, KW-0761 - Advanced/Metastatic Solid Tumors | Phase 1 | Terminated | Pfizer | 24 | 2015-05-01 | 2019-02-27 |
| Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 PF-04518600, PF-04518600 plus PF-05082566 - Neoplasms | Phase 1 | Completed | Pfizer | 174 | 2015-04-23 | 2022-04-21 |
| A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036) PF-05082566, MK-3475 - Advanced Solid Tumors | Phase 1 | Completed | Pfizer | 23 | 2014-08-01 | 2019-02-08 |
| A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab PF-05082566, rituximab - Lymphoma, Non-Hodgkin, Lymphoma, Follicular | Phase 1 | Completed | Pfizer | 190 | 2011-06-21 | 2020-03-17 |
Carcinoma, Non-Small-Cell Lung (3) · Melanoma (3) · Squamous Cell Carcinoma of Head and Neck (3) · Carcinoma, Renal Cell (2) · Lymphoma, Follicular (2) · Lymphoma, Large B-Cell, Diffuse (2) · Neoplasm Metastasis (2) · Stomach Neoplasms (2) · Urinary Bladder Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Colorectal Neoplasms (1) · Head and Neck Neoplasms (1) · Kidney Neoplasms (1) · Liver Neoplasms (1)
Pfizer (5) · M.D. Anderson Cancer Center (3) · City of Hope Medical Center (1) · Dana-Farber Cancer Institute (1) · George W. Sledge Jr. (1) · Kite, A Gilead Company (1)
United States (12) · France (3) · Japan (3) · Australia (2) · Canada (1) · Italy (1) · Netherlands (1) · Poland (1) · Taiwan (1) · United Kingdom (1)
Amir A Jazaeri (1) · Aung Naing (1) · Caron A. Jacobson, MD (1) · Dale R Shepard, MD, PhD (1) · David S Hong (1) · Elizabeth Budde (1) · Esra E Cohen, MD (1) · George Sledge, MD (1) · Michael J Pishvaian, MD, PhD (1)
PMID 29549159, PMID 31801624, PMID 32144134, PMID 34515338, PMID 34615725, PMID 36302562, PMID 37851072, PMID 40139261, PMID 41646361
2014 (1), 2015 (1), P30CA016672 (1)